<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029158</url>
  </required_header>
  <id_info>
    <org_study_id>RN1006-0100</org_study_id>
    <nct_id>NCT01029158</nct_id>
  </id_info>
  <brief_title>A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo</brief_title>
  <acronym>RN1006</acronym>
  <official_title>A Double-blind, Placebo Controlled, Randomised Trial to Compare the Efficacy of 250ng and 500ng RN1006 (a New Formulation of Avotermin) and 250ng and 500ng Juvista (Standard Avotermin Formulation), in the Improvement of Scar Appearance in Healthy Volunteer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renovo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renovo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RN1006 has been developed as a stabilized formulation of avotermin which, when dosed once in
      pre-clinical studies in animals, has shown comparable scar improvement efficacy to the
      standard twice-dosed Juvista formulation. The aim of this trial is to investigate the
      efficacy of RN1006 compared to Juvista in a human volunteer model
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global scar comparison scale</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event incidence including specific assessment of local tolerability at the treated wound site</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Scar Improvement</condition>
  <arm_group>
    <arm_group_label>1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Juvista (Avotermin)</intervention_name>
    <description>250 ng, twice, intradermal injection, standard formulation</description>
    <arm_group_label>1a</arm_group_label>
    <other_name>juvista</other_name>
    <other_name>RN1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RN1006 (Avotermin)</intervention_name>
    <description>250 ng, intradermal injection, twice</description>
    <arm_group_label>1b</arm_group_label>
    <other_name>RN1006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RN1006 (Avotermin)</intervention_name>
    <description>205 ng, Intradermal injection, once</description>
    <arm_group_label>1c</arm_group_label>
    <other_name>RN1006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RN1006 (Avotermin)</intervention_name>
    <description>500ng, intradermal injection, once</description>
    <arm_group_label>1d</arm_group_label>
    <other_name>RN1006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Juvista (Avotermin)</intervention_name>
    <description>250 ng, intradermal injection, twice</description>
    <arm_group_label>2a</arm_group_label>
    <other_name>Juvista</other_name>
    <other_name>RN1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Juvista (Avotermin)</intervention_name>
    <description>500 ng, intradermal injection, once</description>
    <arm_group_label>2b</arm_group_label>
    <other_name>Juvista</other_name>
    <other_name>RN1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Juvista (Avotermin)</intervention_name>
    <description>500 ng, intradermal injection, once</description>
    <arm_group_label>2c</arm_group_label>
    <other_name>Juvista</other_name>
    <other_name>RN1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RN1006 (Avotermin)</intervention_name>
    <description>500 ng, intradermal injection, twice</description>
    <arm_group_label>2d</arm_group_label>
    <other_name>RN1006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1a</arm_group_label>
    <arm_group_label>1b</arm_group_label>
    <arm_group_label>1c</arm_group_label>
    <arm_group_label>1d</arm_group_label>
    <arm_group_label>2a</arm_group_label>
    <arm_group_label>2b</arm_group_label>
    <arm_group_label>2c</arm_group_label>
    <arm_group_label>2d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18-85 years who have given written informed consent

          -  Subjects with a body mass index within range 18-35 kg/m2

          -  Subjects with clinically acceptable results for the laboratory tests specified in the
             trial protocol

          -  Female subjects using a highly effective method (S) of contraception

        Exclusion Criteria:

          -  Subjects who have a history of keloid scarring, surgery within one year of the first
             dosing area

          -  Subjects who have current scars, tattoos, birthmarks, mole within 3 cm of the area to
             be excised

          -  Subjects with any clinically significant medical condition or history of any condition
             which may impair wound healing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Renovo CTU</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Jim Bush</name_title>
    <organization>Renovo</organization>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Comparison of two formulations</keyword>
  <keyword>Improvement of scar appearance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

